Induction of energy expenditure by sitagliptin is dependent on GLP-1 receptor

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Goldsmith, Felicia ^a   Keenan, Michael J ^a   Raggio, Anne M ^a   Ye, Xin ^b   Hao, Zheng ^b   Durham, Holiday ^a   Geaghan, James ^a   Jia, Weiping ^c   Martin, Roy J ^d,e   Ye, Jianping ^b  

^a LOUISIANA STATE UNIVERSITY AGRICULTURAL CENTER   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^d USDAWestern Human Nutrition Research Center   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; LEPTIN; SITAGLIPTIN; STARCH; STREPTOZOCIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL MONITORING; CARBOHYDRATE INTAKE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; ENERGY EXPENDITURE; ENERGY METABOLISM; GLUCAGON LIKE PEPTIDE 1 RECEPTOR BLOOD LEVEL; GLUCOSE METABOLISM; HYPERGLYCEMIA; INSULIN RESISTANCE; KNOCKOUT MOUSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REGULATORY MECHANISM; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM;

MUS;

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; SITAGLIPTIN PHOSPHATE;

EID: 84929095241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126177     Document Type: Article

References (21)

1. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He HD, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005; 48(1): 141-51.
2. Brown DX, Evans M. Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. J Nutr Metab. 2012; 2012: 381713. doi: 10.1155/2012/381713 PMID: 23125920
3. Madsbad S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) - preclinical and clinical results. Best Pract Res Clin Endocrinol Metab. 2009; 23(4): 463-77. doi: 10.1016/j.beem.2009.03.008 PMID: 19748064
4. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract. 201; 90(2): 131-40. doi: 10.1016/j.diabres.2010.07.006 PMID: 20708812
5. Cummings JH, Beatty ER, Kingman SM, Bingham SA, Englyst HN. Digestion and physiological properties of resistant starch in the human large bowel. Br J Nutr. 1996; 75(5): 733-47. PMID: 8695600
6. Englyst HN, Trowell H, Southgate DA, Cummings JH. Dietary fiber and resistant starch. Am J Clin Nutr. 1987; 46(6): 873-4. PMID: 2825503
7. Higgins JA, Higbee DR, Donahoo WT, Brown IL, Bell ML, Bessesen DH. Resistant starch consumption promotes lipid oxidation. Nutr Metab (Lond). 2004; 1(1); 8.
8. Keenan MJ, Zhou J, McCutcheon KL, Raggio AM, Bateman HG, Todd E, et al. Effects of resistant starch, a non-digestible fermentable fiber, on reducing body fat. Obesity (Silver Spring). 2006; 14(9): 1523-34. PMID: 17030963
9. Charrier JA, Martin RJ, McCutcheon KL, Raggio AM, Goldsmith F, Goita M, et al. High fat diet partially attenuates fermentation responses in rats fed resistant starch from high-amylose maize. Obesity (Silver Spring). 2013; 21(11): 2350-5. doi: 10.1002/oby.20362 PMID: 23512798
10. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med. 1996; 2(11: 1254-58. PMID: 8898756
11. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12): 2638-43. PMID: 17130197
12. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49(11): 2564-71. PMID: 17001471
13. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006; 28(10): 1556-68. PMID: 17157112
14. Pannacciulli N, Bunt JC, Koska J, Bogardus C, Krakoff J. Higher fasting plasma concentrations of glucagon-like peptide 1 are associated with higher resting energy expenditure and fat oxidation rates in humans. Am J Clin Nutr. 2006; 84(3): 556-60. PMID: 16960169
15. Osaka T, Endo M, Yamakawa M, Inoue S Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides. 2005; 26(9): 1623-31. PMID: 16112402
16. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA. 2000; 97(12): 6874-9. PMID: 10823914
17. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA. 2003; 100(11): 6825-6830. PMID: 12748388
18. Bradley DP, Kulstad R, Schoeller DA. Exenatide and weight loss. Nutrition. 2010; 26(3): 243-49.
19. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011; 34 Suppl 2: S279-84. doi: 10.2337/dc11-s231 PMID: 21525469
20. Boschmann M, Engeli S, Dobberstein K, Budziarek P, Strauss A, Boehnke J, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009; 94(3): 846-52. doi: 10.1210/jc.2008-1400 PMID: 19088168
21. Sangle GV, Lauffer LM, Grieco A, Trivedi S, Iakoubov R, Brubaker PL. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue. Endocrinology. 2012; 153(2): 564-73. doi: 10.1210/en.2011-1732 PMID: 22186413